Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2017 08:30 ET | Source: Clarus Therapeutics, Inc.

Clarus Re-submits JATENZO NDA Following Positive Results of inTUne Trial

NORTHBROOK, Ill., June 26, 2017 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the re-submission of its New Drug Application (NDA) for JATENZO™ (formerly Rextoro™), the Company’s...
October 13, 2016 08:30 ET | Source: Clarus Therapeutics, Inc.

Clarus Therapeutics Provides Update on Patent Infringement Lawsuit Against Lipocine’s Oral Product for Testosterone Replacement Therapy

Court dismissed lawsuit due to lack of FDA approval for LPCN-1021 and not on merits of case Clarus will be allowed to refile its lawsuit, if necessary NORTHBROOK, Ill., Oct. 13, 2016 (GLOBE...
May 17, 2016 08:30 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Initiates Phase 3 Clinical Trial of Oral Testosterone Replacement Therapy

NORTHBROOK, Ill., May 17, 2016 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of JATENZOTM, its...
January 13, 2014 09:00 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Submits New Drug Application for Rextoro (formerly CLR-610) for the treatment of Low Testosterone

Northbrook, Ill, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the submission of a New Drug Application (NDA) for Rextoro™ (formerly CLR-610), the Company's oral...
January 09, 2014 10:00 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Presents at 32nd Annual J.P. Morgan Healthcare Conference

Northbrook, Ill, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that Robert E. Dudley, Ph.D., chief executive officer of Clarus Therapeutics will present an update on the...
July 01, 2013 08:00 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Bolsters Executive Team with Addition of Chief Medical and Chief Scientific Officers

NORTHBROOK, Ill, July 1, 2013 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the hiring of Theodore M. Danoff, M.D., Ph.D. and Wael A. Salameh, M.D., FACP to fill the newly created...
September 25, 2012 08:00 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Top-line Results Show Oral Testosterone Replacement Candidate, CLR-610, Meets Phase 3 Study Primary Efficacy Endpoint

NORTHBROOK, Ill, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today reported top-line results from the Company's ongoing Phase 3 study of CLR-610, the Company's proprietary oral...
September 19, 2012 08:00 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Strengthens Patent Estate with Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product

NORTHBROOK, Ill, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,241,664 entitled, "Pharmaceutical...
June 21, 2012 08:00 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Appoints Bela S. Denes, M.D. as Chief Medical Officer

NORTHBROOK, Ill, June 21, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of Bela S. Denes, M.D. to the newly created role of chief medical officer. Dr. Denes was...
May 01, 2012 08:22 ET | Source: Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy

NORTHBROOK, Ill, May 1, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that patient enrollment has been completed in the Company's pivotal Phase 3 clinical trial of...

keyboard_arrow_left Previous Page